Diagonal Bio AB (publ) (DIABIO.ST)
SEK 0.02
(4.18%)
SEK 0.02
(4.18%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -11.56 Million SEK | 23.85% |
| 2022 | -15.16 Million SEK | -30.01% |
| 2021 | -11.66 Million SEK | -1819.68% |
| 2020 | -607.55 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.11 Million SEK | -14.34% |
| 2024 Q3 | -1.24 Million SEK | 60.17% |
| 2024 Q1 | -2.72 Million SEK | -11.12% |
| 2023 Q2 | -2.79 Million SEK | 24.4% |
| 2023 FY | -11.54 Million SEK | 23.85% |
| 2023 Q4 | -2.45 Million SEK | 5.8% |
| 2023 Q1 | -3.7 Million SEK | 5.99% |
| 2023 Q3 | -2.6 Million SEK | 6.9% |
| 2022 FY | -15.16 Million SEK | -30.01% |
| 2022 Q4 | -3.93 Million SEK | -12.29% |
| 2022 Q3 | -3.5 Million SEK | 19.29% |
| 2022 Q2 | -4.34 Million SEK | -28.67% |
| 2022 Q1 | -3.37 Million SEK | 5.35% |
| 2021 Q2 | -3.06 Million SEK | -321.73% |
| 2021 FY | -11.66 Million SEK | -1819.68% |
| 2021 Q3 | -4.3 Million SEK | -40.41% |
| 2021 Q4 | -3.56 Million SEK | 17.14% |
| 2021 Q1 | -727 Thousand SEK | -73.37% |
| 2020 Q4 | -419.33 Thousand SEK | -430.8% |
| 2020 Q2 | -278 Thousand SEK | -3871.43% |
| 2020 Q1 | -7000.00 SEK | 0.0% |
| 2020 FY | -607.55 Thousand SEK | 0.0% |
| 2020 Q3 | -79 Thousand SEK | 71.58% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 95.355% |
| Ziccum AB (publ) | -21.56 Million SEK | 46.354% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 29.48% |
| BioArctic AB (publ) | 252.64 Million SEK | 104.578% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -1268.757% |
| Mendus AB (publ) | -100.65 Million SEK | 88.509% |
| Genovis AB (publ.) | 54.22 Million SEK | 121.33% |
| Intervacc AB (publ) | -93.57 Million SEK | 87.64% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 25.438% |
| Active Biotech AB (publ) | -46.48 Million SEK | 75.118% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 164.223% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 79.129% |
| Aptahem AB (publ) | -10.1 Million SEK | -14.461% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 96.403% |
| Kancera AB (publ) | -65.04 Million SEK | 82.218% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 91.408% |
| Fluicell AB (publ) | -26.87 Million SEK | 56.97% |
| Saniona AB (publ) | -81.06 Million SEK | 85.732% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 6.507% |
| Biovica International AB (publ) | -126.07 Million SEK | 90.826% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 72.789% |
| AcouSort AB (publ) | -17.48 Million SEK | 33.859% |
| Xintela AB (publ) | -57.23 Million SEK | 79.793% |
| Abliva AB (publ) | -96.54 Million SEK | 88.02% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 96.439% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -229.986% |
| OncoZenge AB (publ) | -15.9 Million SEK | 27.267% |
| Amniotics AB (publ) | -29.07 Million SEK | 60.217% |
| 2cureX AB (publ) | -36.36 Million SEK | 68.193% |
| CombiGene AB (publ) | -36.3 Million SEK | 68.142% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 20.997% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 96.991% |
| Camurus AB (publ) | 532.35 Million SEK | 102.173% |
| Corline Biomedical AB | -1.78 Million SEK | -546.868% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 93.602% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 72.252% |
| I-Tech AB | 24.43 Million SEK | 147.334% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 98.533% |
| Cyxone AB (publ) | -21.66 Million SEK | 46.604% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 89.085% |
| Biosergen AB | -27.26 Million SEK | 57.579% |
| Cantargia AB (publ) | -290.01 Million SEK | 96.012% |
| NextCell Pharma AB | -43.17 Million SEK | 73.21% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 93.602% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 32.348% |
| Nanologica AB (publ) | -69.96 Million SEK | 83.468% |
| SynAct Pharma AB | -224.49 Million SEK | 94.848% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 73.818% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 51.716% |
| LIDDS AB (publ) | -40.67 Million SEK | 71.564% |
| Lipum AB (publ) | -37.25 Million SEK | 68.954% |
| BioInvent International AB (publ) | -369.94 Million SEK | 96.874% |
| Alzinova AB (publ) | -16.52 Million SEK | 29.996% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 95.437% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -80.91% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 89.949% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 42.569% |
| Simris Alg AB (publ) | -36.63 Million SEK | 68.429% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 92.109% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 96.274% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 89.572% |